• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

byKeerthana PasumarthiandAlex Chan
December 13, 2022
in Chronic Disease, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Primary Sjögren syndrome (pSS) is a debilitating autoimmune disease that is characterized by xerostomia, xerophthalmia, and systemic involvement. While there are currently therapies available for pSS, these are usually corticosteroids and immune-suppressive agents which are used for symptomatic control. These treatment options often are associated with significant adverse effects, and as such, new therapies for pSS are needed. Interleukin 2 (IL-2) is a cytokine which regulates the activity of CD4+ T cells. As dysregulation of T and B cells is involved in the development of pSS, the use of low-dose IL-2 may help improve clinical outcomes in patients with pSS, which this randomized controlled trial aimed to assess. A total of 60 adult participants fulfilling classification criteria for active pSS with at least four weeks of corticosteroid treatments or immunosuppressants were included. Participants were randomly assigned to receive either the blinded recombinant human IL-2 or placebo. Improvement in pSS outcomes were assessed using the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI). The results of this study showed that participants in the low-dose IL-2 group had a greater improvement in the ESSDAI compared to participants in the placebo group. As such, this study supports the use of low-dose IL-2 in treating patients with pSS by enhancing function of the regulatory T cells and B cells.

Click here to read this study in JAMA Rheumatology.

Relevant Reading: Low-dose Interleukin-2 can improve salivary secretion but not lymphocyte proliferation of salivary glands in a murine model of Sjögren’s syndrome

In-Depth [randomized controlled trial]: The present data used data from participants between the ages of 18 to 70 who fulfilled the 2002 American-European Consensus Group classification criteria for Primary Sjögren syndrome (pSS). These participants had active disease at the time of inclusion in the study and had at least a four-week history of stable treatment with corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressants. To examine improvements in pSS outcomes, 60 participants were included. Participants were randomly assigned to one of two groups: the placebo group or the recombinant human IL-2, administered for 12 weeks. Change in pSS symptoms, the study’s primary outcome, was assessed through employing the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI). The ESSDAI included a total score ranging from 0 to 123 points and examined 12 different domains representing various organ systems. Patient’s ESSDAI was assessed at four weeks, 12 weeks, and 24 weeks. Changes in clinical scores from baseline as well as safety outcomes were examined. Changes in immune cells such as T and B cell subsets were additionally evaluated. Statistical analyses included a logistic regression model which adjusted for age, disease duration, and baseline ESSDAI score. The results of this study showed that patients treated with low-dose IL-2 had greater improvements overall from baseline in ESSDAI scores compared to participants in the placebo group (mean difference -2.47, 95%CI -3.75 to -1.18 points). Clinical symptoms such as dryness, pain, and fatigue, improved more significantly in the IL-2 group compared to placebo. The low-dose IL-2 was well tolerated among most participants. Fewer infections were observed in the low-dose IL-2 group compared with placebo and no serious adverse events were noted. Additionally, immunological analysis reveals that treatment with IL-2 resulted in the expansion of regulatory T cells and B cells. This paper ultimately concludes that use of low-dose IL-2 may be effective in improving treatment outcomes among patients with pSS. However, there are several limitations in this paper that should be noted. For instance, the sample size was quite small with only 60 participants included. Replicating this study among various populations with a larger sample is required before applying these findings into clinical practice. As well, further clinical studies examining varying doses of IL-2 may be needed to discern optimal results. Nevertheless, IL-2 therapy for primary Sjögren syndrome is a promising treatment modality in improving patient outcomes.

Image: PD

RELATED REPORTS

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

Self-administered subcutaneous immunoglobulin as an cost-effective alternative to clinic administration

Monoclonal antibody CIS43LS efficacious in preventing malaria in Mali

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immunologyrheumatologySjögren’s Syndrome
Previous Post

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

Next Post

#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment

RelatedReports

Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults

January 24, 2023
Influenza vaccine not associated with increased risk of epilepsy in children
Public Health

Self-administered subcutaneous immunoglobulin as an cost-effective alternative to clinic administration

November 28, 2022
RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time
Infectious Disease

Monoclonal antibody CIS43LS efficacious in preventing malaria in Mali

November 23, 2022
Infectious Disease

Moderna mRNA COVID-19 vaccine is safe in children six months to five years of age

November 16, 2022
Next Post
#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment

#VisualAbstract: Expectant management of patent ductus arteriosus in extremely premature infants was non-inferior to early ibuprofen treatment

Late gestation antidepressant use linked to postpartum hemorrhage

Monofilament suture does not reduce pregnancy loss compared to braided suture for cervical cerclage

UTI associated with increased risk of preeclampsia

Carotid and femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options